Using "rationally designed drugs" rationally

Lancet

Volumn 361, Issue 9371, 2003, Pages 1758-1759

  Brugarolas, Jim ^a   Clark, Jeffrey W ^a,b   Chabner, Bruce ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BCR ABL PROTEIN; CYTOTOXIC AGENT; ENZYME; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR; HYDROXYUREA; IMATINIB; INTERFERON; MATRIX METALLOPROTEINASE; PROTEIN; PROTEIN FARNESYLTRANSFERASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RNA; STEM CELL FACTOR;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARCINOGENESIS; CARCINOMA; CELL GROWTH; CELL TRANSFORMATION; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CORRELATION ANALYSIS; DISEASE MODEL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG USE; ENZYME INHIBITION; EXTRACELLULAR MATRIX; GASTROINTESTINAL TUMOR; GENE EXPRESSION; GENE MUTATION; GENOMICS; HUMAN; MOLECULAR BIOLOGY; NOTE; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; PROTEOMICS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR GROWTH;

EID: 0038101471     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)13446-0     Document Type: Note

References (13)

1. O'Brien S.G., Guilhot F., Larson R.A., et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic- phase chronic myeloid leukemia. N Engl J Med. 348:2003;994-1004.
2. Demetri G.D. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor Imatinib mesylate (STI571). Eur J Cancer. 38:(suppl 5):2002;S52-S59.
3. Rothenberg M.L., Carbone D.P., Johnson D.H. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer. 3:2003;303-309.
4. Daley G.Q., Van Etten R.A., Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 247:1990;824-830.
5. Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P.K., Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature. 344:1990;251-253.
6. Kelliher M.A., McLaughlin J., Witte O.N., Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA. 87:1990;6649-6653.
7. Szczylik C., Skorski T., Nicolaides N.C., et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science. 253:1991;562-565.
8. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 2:1996;561-566.
9. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science. 295:2002;2387-2392.
10. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 344:2001;1031-1037.
11. le Coutre P., Mologni L., Cleris L., et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst. 91:1999;163-168.
12. Brugarolas J., Haynes B.F., Nevins J.R. Towards a genomic-based diagnosis. Lancet. 357:2001;249-250.
13. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature. 400:1999;464-468.